Shanghai perhum therapeutics co. ltd
Webb22 maj 2024 · Shanghai PerHum Therapeutics Co., Ltd. Collaborator: Shanghai Zhongshan Hospital Information provided by (Responsible Party): Shanghai PerHum Therapeutics … Webb12 mars 2024 · The company is developing logic gated CAR-T platforms to advance TME-restricted cellular therapies for solid tumors, platforms that will allow for same-day, rapid point of care (rPOC) administration for solid or liquid tumors, and highly scalable systems for global therapy deployment, beginning in Asia. Learn more at exumabio.com. Media …
Shanghai perhum therapeutics co. ltd
Did you know?
WebbPerhum therapeutics has developed a modified chimeric antigen receptor (CAR)-T cell for treating tumors. The company uses patented CAB-CAR-T technology to evaluate CCT … WebbExpertise in innovatively developing novel therapeutic recombinant proteins, gene therapy candidates for treatment of autoimmune diseases and exploring the immunology …
WebbCompany: Exuma Biotech, Sunterra Biotech. Drug class: HER2-targeted CAR-T immunotherapy. Associations (0) News. ... CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors (clinicaltrials.gov) P1, N=15, Recruiting, Shanghai PerHum Therapeutics Co., Ltd. Trial completion date: Apr 2024 --> Oct 2024 Trial … WebbFind business data of PerHum Therapeutics. Know the headquarter data such: ... Company Focus. Core Business. Website-Corporate Office and Headquarter Office address: Unit …
WebbNews for CCT301-38 / Sunterra Biotech, Exuma Biotech. Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma (clinicaltrials.gov) - P1/2; N=66; Active, not recruiting; Sponsor: Shanghai PerHum Therapeutics Co., Ltd.; Trial completion date: Mar 2035 Jun 2024; Trial primary … Webb14 nov. 2024 · Published. November 14, 2024. DelveInsight’s, “ Metastatic Renal Cell Carcinoma Pipeline Insight, 2024,” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in ...
Webb15 feb. 2024 · DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering …
Webb12 okt. 2024 · HER2-Positive Breast Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market … gmail login info for meWebb21 okt. 2024 · Shanghai PerHum Therapeutics Co., Ltd. (Industry) Overall Status Active, not recruiting CT.gov ID NCT03393936 Collaborator Shanghai Public Health Clinical Center (Other) 66 Enrollment 1 Location 2 Arms 63.1 Anticipated Duration (Months) gmail login judy.g.shephard gmail.comWebbReports on Shanghai Perhum Therapeutics Co., Ltd include information such as : Shanghai Perhum Therapeutics Co., Ltd is headquartered in Shanghai : The Business report also … gmail login low bandwidthWebbStatus: Active not recruiting: Phase: Phase 1: Sponsor: Shanghai PerHum Therapeutics Co., Ltd. Start date: May 2024: End date: June 2024: Enrollment: 18 participants gmail login interfaceWebb6 maj 2024 · Shanghai PerHum Therapeutics Co., Ltd. ClinicalTrials.gov Identifier: NCT05128786 Other Study ID Numbers: CCT301-38-SAR First Posted: Nov 22, 2024 Last … bolsos tommyWebbShanghai PerHum Therapeutics Co, Ltd: BTLA: 2024: 2024: Monoantibody: JS004: Shanghai Junshi Bioscience Co, Ltd: Nectin4/FAP dual target: 2024: 2024: CAR-T cell: … gmail login in boxWebb5 okt. 2024 · New York, USA, Oct. 05, 2024 (GLOBE NEWSWIRE) -- Metastatic Renal Cell Carcinoma Clinical Trials Pipeline Landscape Analysis of 45+ Companies by … gmail login mail change password